Ghrelin ameliorates diabetes-associated behavioral deficits and NLRP3 inflammasome activation via autophagic flux enhancement. (May 2022)
- Record Type:
- Journal Article
- Title:
- Ghrelin ameliorates diabetes-associated behavioral deficits and NLRP3 inflammasome activation via autophagic flux enhancement. (May 2022)
- Main Title:
- Ghrelin ameliorates diabetes-associated behavioral deficits and NLRP3 inflammasome activation via autophagic flux enhancement
- Authors:
- Han, Wenxiu
Cui, Changmeng
Zhang, Hailiang
Guo, Yujin
Xie, Dadi
Zhang, Wenyuan
Wang, Changshui
Yang, Mengqi
Jiang, Pei - Abstract:
- Abstract: Ghrelin has recently been associated with the development of diabetes comorbid with depression, but its underlying molecular mechanisms remains poorly understood. Here, molecular and histological methods were applied both in vivo and in vitro studies to investigate the mechanisms of ghrelin in diabetes comorbid with depression. Our results demonstrated the anti-depressive, anxiolytic, and neuroprotective effects of ghrelin, as evidenced by the amelioration of anxiety- and depression-like behaviors, reduction in apoptosis, and preservation of neuron integrity in streptozotocin (STZ)-treated rats. STZ treatment induced M1-phenotypic microglial polarization, accompanied by neuroinflammation, which was reversed by ghrelin treatment. Further exploration showed that autophagy was inhibited, the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome and nuclear factor (NF)-κB signaling pathway were activated in STZ rats. In line with the in vivo results, ghrelin could suppress the NLRP3 inflammasome and NF-κB signaling pathway activation via the amelioration of impaired autophagic flux in microglial BV2 cells. Importantly, clinical evidence further verified the anti-inflammatory and antidepressant effects of ghrelin. Collectively, these results suggested that ghrelin ameliorates diabetes-associated behavioral deficits and NLRP3 inflammasome activation via autophagic flux enhancement, highlighting the importance of ghrelin as a potential target of immuneAbstract: Ghrelin has recently been associated with the development of diabetes comorbid with depression, but its underlying molecular mechanisms remains poorly understood. Here, molecular and histological methods were applied both in vivo and in vitro studies to investigate the mechanisms of ghrelin in diabetes comorbid with depression. Our results demonstrated the anti-depressive, anxiolytic, and neuroprotective effects of ghrelin, as evidenced by the amelioration of anxiety- and depression-like behaviors, reduction in apoptosis, and preservation of neuron integrity in streptozotocin (STZ)-treated rats. STZ treatment induced M1-phenotypic microglial polarization, accompanied by neuroinflammation, which was reversed by ghrelin treatment. Further exploration showed that autophagy was inhibited, the NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome and nuclear factor (NF)-κB signaling pathway were activated in STZ rats. In line with the in vivo results, ghrelin could suppress the NLRP3 inflammasome and NF-κB signaling pathway activation via the amelioration of impaired autophagic flux in microglial BV2 cells. Importantly, clinical evidence further verified the anti-inflammatory and antidepressant effects of ghrelin. Collectively, these results suggested that ghrelin ameliorates diabetes-associated behavioral deficits and NLRP3 inflammasome activation via autophagic flux enhancement, highlighting the importance of ghrelin as a potential target of immune regulation in diabetes comorbid with depression. Graphical Abstract: ga1 Highlights: Ghrelin ameliorates diabetes-associated behavioral deficits and NLRP3 inflammasome activation via autophagic flux enhancement. Clinical data firstly verified the contribution of ghrelin and inflammation interaction in diabetes comorbid with depression. Ghrelin may be considered as a potential therapeutic target for diabetic patients comorbid with depression. … (more)
- Is Part Of:
- Pharmacological research. Volume 179(2022)
- Journal:
- Pharmacological research
- Issue:
- Volume 179(2022)
- Issue Display:
- Volume 179, Issue 2022 (2022)
- Year:
- 2022
- Volume:
- 179
- Issue:
- 2022
- Issue Sort Value:
- 2022-0179-2022-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-05
- Subjects:
- Ghrelin -- Diabetes -- Depression -- Neuroinflammation -- Autophagy -- NF-κB signaling pathway
Pharmacology -- Periodicals
Pharmacology -- Periodicals
Research -- Periodicals
Médicaments -- Recherche -- Périodiques
Pharmacologie -- Périodiques
615.105 - Journal URLs:
- http://www.sciencedirect.com/science/journal/10436618 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.phrs.2022.106224 ↗
- Languages:
- English
- ISSNs:
- 1043-6618
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6446.550000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21519.xml